What does FDA’s approval of generic liraglutide mean for obesity care?

The FDA has approved a generic version of liraglutide injection, expanding access to obesity treatment by lowering costs and broadening eligibility across adults and adolescents, though safety monitoring remains essential. A JAMA Network Open study found that overweight older adults had lower 30-day mortality after elective surgery compared to those of normal weight, highlighting the “obesity paradox” in surgical risk assessment. Finally, a new rapid, culture-free diagnostic method for sepsis can identify pathogens within two hours using microfluidics and deep learning, offering significant potential to improve survival in critically ill patients.